Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study
- PMID: 17689296
- PMCID: PMC2083573
- DOI: 10.1016/j.cgh.2007.05.020
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study
Abstract
Background & aims: Intrahepatic and extrahepatic cholangiocarcinomas are rare and highly malignant cancers of the bile duct. Although the incidence of extrahepatic cholangiocarcinoma (ECC) has remained constant, the incidence of intrahepatic cholangiocarcinoma (ICC) has increased in the United States. Because the etiology of both tumors is poorly understood, a population-based case-control study was conducted to examine the association of ECC and ICC with preexisting medical conditions.
Methods: Medical conditions among 535 ICC patients, 549 ECC patients (diagnosed 1993-1999), and 102,782 cancer-free controls were identified by using the Surveillance, Epidemiology and End Results-Medicare databases. Logistic regression analysis was used to calculate adjusted odds ratios.
Results: In addition to established risk factors (choledochal cysts, cholangitis, inflammatory bowel disease), several other conditions were significantly associated with ECC and ICC: biliary cirrhosis (ECC, ICC: P < .001), cholelithiasis (ECC, ICC: P < .001), alcoholic liver disease (ECC, P < .001; ICC, P = .01), nonspecific cirrhosis (ECC, ICC: P < .001), diabetes (ECC, ICC: P < .001), thyrotoxicosis (ECC, P = .006; ICC, P = .04), and chronic pancreatitis (ECC, ICC: P < .001). Conditions only associated with ICC were obesity (ECC, P = .71; ICC, P = .01), chronic nonalcoholic liver disease (ECC, P = .08; ICC, P = .02), HCV infection (ECC, P = .67; ICC, P = .01), and smoking (ECC, P = .07; ICC, P = .04).
Conclusions: Several novel associations with ECC and ICC were identified. HCV infection, chronic nonalcoholic liver disease, and obesity, all of which are increasing in incidence, and smoking were associated only with ICC, suggesting that these conditions might explain the divergent incidence trends of the tumors.
Similar articles
-
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare.PLoS One. 2017 Oct 19;12(10):e0186643. doi: 10.1371/journal.pone.0186643. eCollection 2017. PLoS One. 2017. PMID: 29049401 Free PMC article.
-
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a case-control study in China.Liver Int. 2010 Feb;30(2):215-21. doi: 10.1111/j.1478-3231.2009.02149.x. Epub 2009 Oct 14. Liver Int. 2010. PMID: 19840244
-
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study.Am J Gastroenterol. 2007 May;102(5):1016-21. doi: 10.1111/j.1572-0241.2007.01104.x. Epub 2007 Feb 23. Am J Gastroenterol. 2007. PMID: 17324130
-
The epidemiology of cholangiocarcinoma.Semin Liver Dis. 2004 May;24(2):115-25. doi: 10.1055/s-2004-828889. Semin Liver Dis. 2004. PMID: 15192785 Review.
-
Intrahepatic cholangiocarcinoma: new insights in pathology.Semin Liver Dis. 2011 Feb;31(1):49-60. doi: 10.1055/s-0031-1272839. Epub 2011 Feb 22. Semin Liver Dis. 2011. PMID: 21344350 Review.
Cited by
-
Diabetes and PKM2 affect prognosis in patients with intrahepatic cholangiocarcinoma.Oncol Lett. 2020 Nov;20(5):265. doi: 10.3892/ol.2020.12128. Epub 2020 Sep 21. Oncol Lett. 2020. PMID: 32989399 Free PMC article.
-
Incidence and Long-Term Outcomes of Biliary Tract Cancers in Olmsted County, Minnesota from 1976 to 2018.Cancers (Basel). 2024 Jul 31;16(15):2720. doi: 10.3390/cancers16152720. Cancers (Basel). 2024. PMID: 39123448 Free PMC article.
-
Bile duct carcinoma recurrence in the papillary region in a long-term survivor of hilar cholangiocarcinoma: a case report.J Med Case Rep. 2016 Oct 26;10(1):299. doi: 10.1186/s13256-016-1073-6. J Med Case Rep. 2016. PMID: 27784337 Free PMC article.
-
Tumor-associated macrophages: orchestrators of cholangiocarcinoma progression.Front Immunol. 2024 Sep 3;15:1451474. doi: 10.3389/fimmu.2024.1451474. eCollection 2024. Front Immunol. 2024. PMID: 39290697 Free PMC article. Review.
-
Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update.Cancers (Basel). 2023 Jan 13;15(2):494. doi: 10.3390/cancers15020494. Cancers (Basel). 2023. PMID: 36672443 Free PMC article. Review.
References
-
- Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303–1314. - PubMed
-
- Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology. 2005;128:1655–1667. - PubMed
-
- Bergquist A, Glaumann H, Lindberg B, Broome U. Primary sclerosing cholangitis can present with acute liver failure: Report of two cases. J Hepatol. 2006;44:1005–1008. - PubMed
-
- Broome U, Glaumann H, Lindstom E, Loof L, Almer S, Prytz H, Sandberg-Gertzen H, Lindgren S, Fork FT, Jarnerot G, Olsson R. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC) J Hepatol. 2002;36:586–589. - PubMed
-
- Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, McCashland TM, Reddy KR, Zervos X, Anbari MA, Hoen H. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology. 2000;31:7–11. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical